Type 2 Diabetes
Fenofibrate seems more effective in reducing chylomicron response in diabetes
Published in Obesity and Diabetes Week, September 11th, 2006
"Postprandial lipid abnormalities might contribute to the excess of cardiovascular risk typical of type 2 diabetic patients. The study evaluated the effects of atorvastatin (20 mg/d) vs. fenofibrate (200 mg/d) on postprandial lipids in type 2 diabetic patients with mixed hyperlipidaemia," scientists writing in the European Journal of Clinical Investigation report.
C. Iovine and colleagues at the University of Naples Federico II described, "Eight type 2 diabetic patients, male/female (M/F) 6/2, age...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Diabetes & Obesity
Chromium (D-Phenylalanine)3 shows insulin-sensitizing and cholesterol-lowering effects - Diabetes Therapy
Glucagon-like peptide-1 analog improves glucose tolerance in obese diabetic mice - Obesity Risk Factors
Insulin resistance impacts risk for obesity-related metabolic comorbidities in adolescents - Obesity Therapy
Sibutramine plus behavior therapy program reduced BMI and body weight in obese adolescents - Weight Loss
Magenstrasse and Mill procedure combined with Roux-en-Y gastric bypass improves weight loss - Adipose Tissue
Adipose cells functions and proliferations may be regulated by varying immunological mechanism - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
